Clinical trial

Opioid Free Anesthesia in Total Hip Arthroplasty. A Randomized, Controlled and Triple-blind Clinical Trial

Name
2021/04
Description
Total hip arthroplasty (THA) is one of the most common orthopedic surgical procedure and is associated with severe pain in the immediate postoperative period, thus limiting early recovery. Postoperative pain management in THA requires multimodal analgesia, combining drugs and injection of a local anesthetic (LA). But, the best anesthesia strategy to provide optimal postoperative analgesia in THA remains controversial. Opioid free anesthesia could limit the episodes of hyperalgesia as well as tolerance and addiction to opioids. The hypothesis of this study is that an opioid free anesthesia using dexmedetomidine could improve analgesia after THA. The main objective of this monocenter, prospective, randomized, triple-blind, controlled trial is to assess the interest of opioid free anesthesia using dexmedetomidine on morphine consumption after THA.
Trial arms
Trial start
2022-02-03
Estimated PCD
2023-02-02
Trial end
2023-02-02
Status
Completed
Phase
Early phase I
Treatment
Sufentanil
Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
Arms:
Control group
Dexmedetomidine
Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.
Arms:
OFA group
Size
80
Primary endpoint
Postoperative analgesia, defined by the oxycodone consumption in the first 24 hours post-surgery
24 hours
Eligibility criteria
Inclusion Criteria: * 18 years and older, * Undergoing outpatient primary total hip arthroplasty under general anesthesia with laryngeal mask, * Consent for participation, * Affiliation to a social security system Exclusion Criteria: * Heart rate \< 60 bpm * Chronic pain syndrome requiring preoperative morphine use (class 3) * Contraindication for: paracetamol, ketoprofen, nefopam, oxycodone, propofol, ketamine, cisatracurium, sufentanyl, ropivacaine. * Contraindication for dexmedetomidine: hypersensitivity to the active substance or to any of the excipients, advanced cardiac block (grade 2 or 3) unless paced ; uncontrolled hypotension ; acute cerebrovascular conditions * Contraindication to laryngeal mask : old insulin-dependent diabetes, gastro-oesophageal reflux, morbid obesity (defined by BMI \> 35) * Pregnant or breastfeeding women * Women of child bearing potential without contraception (any contraceptive method used regularly and appropriately with a low failure rate: \<1% per year), * A mental or linguistic inability to understand the study, * Patient under protection of the adults (guardianship, curators or safeguard of justice), * Patient included or planning to be included in another clinical trial relating to medications
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 80, 'type': 'ACTUAL'}}
Updated at
2023-02-22

1 organization

2 products

1 indication

Organization
CMC Ambroise Paré
Product
Sufentanil